Targeting the insulin growth factor receptor 1
Open accessAbstract
The IGF axis is a tightly controlled endocrine system that regulates cell growth and development, known to have an important function in cancer biology. IGF1 and IGF2 can promote cancer growth in a GH-independent manner both through paracrine and autocrine secretion and can also confer resistance to chemotherapy and radiation. Many alterations of this system have been found in neoplasias, including increased expression of ligands and receptors, loss of heterozygosity of the IGF2 locus and increased IGF1R gene copy number. The IGF1 network is an attractive candidate for targeted therapy, including receptor blockade with monoclonal antibodies and small molecule inhibitors of receptor downstream signaling. This article reviews the role of the IGF axis in the initiation and progression of cancer, and describes the recent advances in IGF inhibition as a therapeutic tool.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Drugs targeting the IGF-1R system are currently being tried in phase 1 and phase 2 trials in several tumor entities.
“Drugs targeting the IGF-1R system are currently being tried in phase 1 and phase 2 trials in several tumor entities (315).”
From Adrenocortical carcinoma (2014) · cites this paper as [315]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 137 · Cited by 88
- Authors
- Arnaldez, F. I., & Helman, L. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Arnaldez, Fernanda I.
- Venue
- Hematology/Oncology Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 26
- Issue
- 3
- Pages
- 527-542
- ISSN
- 0889-8588 (ISSN-L)
- PMC
- PMC3334849
- OpenAlex
- W2084545997
- Cited by
- 88
- References
- 137
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 3 · 2017: 6 · 2016: 16 · 2015: 22 · 2014: 15 · 2013: 10 · 2012: 2
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hematology/Oncology Clinics of North America (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 CA999999)
- National Cancer Institute (Y99 CA999999)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- IGF-1 receptor, IGF axis, insulin-like growth factor I, insulin-like growth factor II, tumor progression, chemoresistance, radioresistance (biology), loss of heterozygosity, monoclonal antibodies, small molecule inhibitors, targeted therapy
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Insulin-Like Growth Factor I, Insulin-Like Growth Factor II, Neoplasms, Signal Transduction, Receptor, IGF Type 1, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
